Exclusive Summary

• Global patents expired with originator approved since the late 1980s; generics mature, while ophthalmic/topical forms remain scarce and differentiating; HBV has ~296 million chronic infections and ~1.1 million new cases annually, sustaining interferon demand in resource-limited settings; WHO/EASL/APASL keep interferon (PEG preferred) as an HBV option, with non-PEG α2b used where PEG-IFN is inaccessible; EP/USP/CP/WHO standard, high purity/activity and multiple formulations support multi-specialty uptake and registrations; significant cost advantage versus originator and PEG-IFN enabling tender and budget-constrained access.

Asset Materials

Contact Us for Full Materials